TNFSF10, TNF superfamily member 10, 8743

N. diseases: 445; N. variants: 10
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.070 Biomarker group BEFREE In this study, using the first described C57BL/6 (B6) TRAIL-sensitive experimental tumor models, we have characterized the innate and adaptive immune components involved in the primary rejection phase of an anti-mouse DR5 (mDR5) mAb, MD5-1 in established MC38 colon adenocarcinomas. 20505139 2010
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.070 GeneticVariation group BEFREE In this study, three different lung cancer cell lines and three different primary cell cultures established from patients with lung cancer (two patients with squamous cell lung carcinoma and one with adenocarcinoma) were screened for sensitivity to adenoviral delivery of TRAIL. 17187448 2007
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.070 AlteredExpression group LHGDN TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. 16751802 2006
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.070 AlteredExpression group BEFREE These results suggest that Adv-caspase-8 may be a good combination partner of TRAIL and enables TRAIL to be a more potent anticancer agent in a wide range of adenocarcinoma cells which demonstrate low expression of caspase-8. 15645141 2005
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.070 GeneticVariation group LHGDN Reconstitution of caspase-3 confers low glucose-enhanced tumor necrosis factor-related apoptosis-inducing ligand cytotoxicity and Akt cleavage. 15041704 2004
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.070 Biomarker group LHGDN HDAI may be useful as an adjuvant agent for TRAIL in the treatment of human colonic adenocarcinomas that are resistant to TRAIL. 11956660 2002
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.070 Biomarker group BEFREE Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)/Apo2L has been recently identified as important in promoting programmed cell death in breast and colon adenocarcinomas. 10960444 2000